Accsys Technologies (LON:AXS) has had a rough three months with its share price down 5.4%. We, however decided to ...

Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that ...

Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...

The US Food and Drug Administration (FDA) has accepted for filing Axsome Therapeutics’ supplemental New Drug Application (NDA ...

Shares of Axis Capital Holdings AXS have gained momentum. The stock is trading above its 50 and 200-day simple moving average ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...

Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved ...

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.

AXS, the global advanced ticketing and live event technology company, has announced two key leadership appointments as part of its continued technology transformation and global growth. Nikhil Bobde ...

AXS-05 demonstrated a statistically significant mean reduction from baseline in the MADRS total score of 7.3 points for AXS-05 compared to 4.9 points for placebo at Week 1 (p=0.007), with statistical ...

New hires underscore ticketing company's global growth strategy and focus on next-gen fan experiences By Dave Brooks AXS is bolstering its executive team with two major technology appointments. The ...

Gravel bikes are arguably the best thing to hit the bike scene in recent memory. I remember first seeing them on the road and trails a decade-and-a-half ago, and being extremely skeptical about what ...